Drug-Resistant Tuberculosis: Introducing a Game-Changing Treatment Regimen in Kenya

May 7, 2024Mbetera FelixUncategorized2

Kenya is gearing up for a groundbreaking shift in the management of Drug-Resistant Tuberculosis (DR-TB) with the introduction of a new shorter regimen set to commence on June 1, 2024.

Spearheaded by the Division of National Tuberculosis and Other Lung Diseases, the initiative involves capacity-building Training of Trainers (TOT) sessions. Experts from all 47 counties will lead the training of healthcare workers in various facilities.

This move comes at a crucial time as DR-TB cases continue to rise globally, with only a fraction of patients receiving life-changing treatment. The World Health Organization (WHO) has recommended a novel, shorter regimen, known as BPaL(M), which offers better outcomes and significantly shortens the duration of treatment. This regimen, composed of bedaquiline, pretomanid, linezolid, and moxifloxacin, is a game-changer in the fight against DR-TB, promising improved quality of life for patients and easing the burden on healthcare systems.

With updated guidelines emphasizing the urgency of transitioning to these new treatment regimens, Kenya stands poised to make significant strides in combatting DR-TB and improving patient outcomes.